NCT04550494 2026-03-19
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05071937 2025-06-22
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT02127151 2021-08-06
PANDA
University College, London
Phase 2 Withdrawn
NCT02836028 2018-09-18
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Pfizer
Phase 2 Withdrawn